UnknownNot Applicable

Magnetocardiography as a Noninvasive Diagnostic Strategy for Identifying Coronary Allograft Vasculopathy

United States40 participantsStarted 2023-05-23

Plain-language summary

Purpose: To show early feasibility of magnetocardiography (MCG) to identify coronary Cardiac positron emission tomography (PET) is the preferred non-invasive tests to assess for CAV and incorporation of quantitative myocardial blood flow (MBF) assessment improves diagnostic accuracy. Based on ISHLT criteria, the following have been proposed for diagnosis of CAV by PET:

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * ≥ 18 years of age at the time of enrollment Willing to provide written informed consent Completed cardiac PET within the last 2 weeks No changes to medication or intervention since the PET was completed Exclusion Criteria: * Patients unable to fit into device Patients unable to lie supine for 5 minutes Patients with implanted ferromagnetic objects above the costal margin of the rib cage (implanted pacemakers, cardioverter/defibrillators, infusion pumps, and/or neuro stimulators). NOTE: Sternotomy wires stents are acceptable Implanted pacemakers or cardioverter/defibrillators Implanted infusion pumps and/or neuro stimulators Severe claustrophobia

What they're measuring

To compare the performance (diagnostic capabilities) of magnetocardiography in the diagnosis of coronary vasculopathy (CAV) as compared to PET as the currently accepted gold standard non-invasive tool.

Timeframe: 6 months

Trial details

NCT IDNCT05751915

SponsorGenetesis Inc.

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2023-12-30

Contact for this trial

Melanie L Gruen, MS

8594684273 melanie.gruen@genetesis.com

View on ClinicalTrials.gov More Coronary Allograft Vasculopathy (CAV) trials